If you click on "Accept", you agree to the storage of cookies on your device in order to improve website navigation, analyze website usage and support our marketing efforts.
Edit this text by going to Appearance > Menus in the CMS. Then select the Primary Navigation and update the menu items accordingly.
Together with our patients, we strive to extend survival in some of the most aggressive forms of cancer by developing and commercializing our innovative therapy. Learn more about our story, from our founding in Haifa, Israel in 2000 to having grown into a global oncology company today.
Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.
We join together with patients, caregivers and advocacy partners in their dedication to redefine living with cancer.
Corporate social responsibility is important to us, and patients remain at the heart of the work we do every day.
Novocure is dedicated to supporting independent organizations with shared goals related to advancing medical care and improving patient outcomes.
The science of Tumor Treating Fields extends beyond glioblastoma and mesothelioma. Novocure has ongoing or completed clinical trials investigating our therapy in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
Tumor Treating Fields have shown a consistent anti-mitotic effect in our preclinical and clinical research spanning more than two decades.
The science of Tumor Treating Fields extends beyond glioblastoma and mesothelioma. Novocure has ongoing or completed clinical trials investigating our therapy in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
View our press kit, read stories about our company and reach out if you’d like an interview or more information about Novocure.
Stay on top of Novocure news by viewing our latest announcements.
Learn more about our company and our mission through stories about patients, our colleagues, our collaborators and our culture.
learn more
Learn more about our company and our mission through stories about patients, our colleagues, our collaborators and our culture.
Novocure to Report Third Quarter 2017 Financial Results
ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2017 on Thursday, October 26, 2017, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three and nine months ended September 30, 2017, at 8 a.m. EDT on Thursday, October 26, 2017.
Analysts and investors can participate in the conference call by dialing 855-442-6895 for domestic callers and 509-960-9037 for international callers, using the conference ID 75156706. The webcast can be accessed live from the Investor Relations page of Novocure’s website, https://www.novocure.com/investor-relations, and will be available for replay for at least 14 days following the call.
About Novocure
Novocure is an oncology company developing a profoundly different cancer treatment utilizing a proprietary therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure’s commercialized product, Optune, is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed clinical trials investigating TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.
Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.
